[Variable extent of platelet responsiveness to clopidogrel inhibition: "clopidogrel resistance"?]

Area of Science:

• Cardiology
• Pharmacology
• Biochemistry

Background:

• Percutaneous coronary angioplasty (PCA) with stenting reduces thrombotic occlusion risk using clopidogrel and aspirin.
• Despite dual antiplatelet therapy, acute/subacute stent thrombosis occurs in 1-2% of patients.
• Significant interindividual variability in clopidogrel response suggests "clopidogrel resistance."

Purpose of the Study:

• To explore the concept of "clopidogrel resistance" and its association with thrombotic events post-PCA.
• To identify factors contributing to variable clopidogrel responsiveness.
• To evaluate the utility of laboratory tests for assessing "clopidogrel resistance."

Main Methods:

• Review of literature on clopidogrel responsiveness and stent thrombosis.
• Analysis of factors influencing clopidogrel metabolism and platelet function.
• Discussion of diagnostic laboratory tests for "clopidogrel resistance."

Main Results:

• "Clopidogrel resistance" is linked to an increased risk of thrombotic events after coronary angioplasty.
• Factors like enteric absorption, CYP3A4 metabolism, P2Y12 receptor variations, and comorbidities (diabetes) contribute to resistance.
• Laboratory tests may identify patients with "clopidogrel resistance."

Conclusions:

• "Clopidogrel resistance" is a significant clinical issue in patients undergoing PCA.
• Identifying resistant patients via laboratory testing could enable personalized antiplatelet therapy.
• Higher clopidogrel doses may improve platelet inhibition in resistant individuals, potentially reducing thrombotic risk.